Loading
A phase 1/2 trial of Opevesostat, Olaparib, Docetaxel, Cabazitaxel, Dexamethasone and Prednisone in prostate cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) is a phase 1/2 interventional study registered as NCT06353386 by Merck Sharp & Dohme LLC, with 220 participants planned, started 2024-05-20 and due to reach its primary completion in 2029-01-15. Interventions recorded: Opevesostat, Olaparib, Docetaxel, Cabazitaxel, Fludrocortisone acetate and Dexamethasone.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Opevesostat, Docetaxel, Metastatic castration-resistant prostate cancer, Merck & Co. (MSD) and the tag pipeline.
Shares Prednisone, Dexamethasone, Docetaxel, Prostate cancer and the tag pipeline.
Shares Opevesostat, Dexamethasone, Merck & Co. (MSD) and the tag pipeline.
Shares Prednisone, Docetaxel, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Prednisone, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Olaparib, Merck & Co. (MSD) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/